LPCN · NASDAQ · Biotechnology

Lipocine (LPCN)

Develops oral therapies and licenses approved testosterone product TLANDO to commercialization partners.

$2.39
At close+0.09 (+3.91%)

Breakdown13F · 13D/G · Form 4

Institutions46 holders · as of Mar 31, 202637.83%3.12M shares
Insiders2 holders · as of Apr 7, 20264.42%364.5K shares
Otherremainder57.75%4.76M shares

8.24M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesEvidence
Ikarian Capital, LLCInstitution
6.17%508,55613Fas of Mar 31, 2026
Squadron Capital Management LLCInstitution
5.46%450,00013Fas of Mar 31, 2026
Squadron Master Fund LPInstitution
5.46%450,00013Gfiled May 15, 2026
Eversept Partners, LPInstitution
3.58%294,98913Fas of Mar 31, 2026
Rosalind Advisors, Inc.Institution
2.69%221,61613Fas of Mar 31, 2026
John W. HiguchiInsiderdirector
2.47%203,797Form 4filed Apr 7, 2026
Vanguard Capital Management LLCInstitution
2.43%200,66813Fas of Mar 31, 2026
Aigh Capital Management LLCInstitution
2.43%200,00013Fas of Mar 31, 2026
Mahesh V. PatelInsiderdirector, officer: Chief Executive Officer
1.95%160,679Form 4filed Apr 6, 2026
Stempoint Capital LPInstitution
1.95%160,42013Fas of Mar 31, 2026
Boothbay Fund Management, LLCInstitution
1.70%140,48713Fas of Mar 31, 2026
Seven Fleet Capital Management LPInstitution
1.52%124,94213Fas of Mar 31, 2026
Birchview Capital, LPInstitution
1.36%111,78613Fas of Mar 31, 2026
BlackRock, Inc.Institution
1.08%89,27213Fas of Mar 31, 2026
Mink Brook Asset Management LLCInstitution
0.81%66,81213Fas of Mar 31, 2026
Geode Capital Management, LLCInstitution
0.77%63,13513Fas of Mar 31, 2026
Exome Asset Management LLCInstitution
0.74%60,86113Fas of Mar 31, 2026
Diadema Partners LPInstitution
0.61%50,00013Fas of Mar 31, 2026
J. Goldman & Co LPInstitution
0.51%42,17013Fas of Mar 31, 2026
Renaissance Technologies LLCInstitution
0.47%38,49713Fas of Mar 31, 2026
Two Sigma Investments, LPInstitution
0.41%33,75013Fas of Mar 31, 2026
Vanguard Fiduciary Trust CoInstitution
0.39%32,41313Fas of Mar 31, 2026
Citadel Advisors LLCInstitution
0.35%29,08813Fas of Mar 31, 2026
Susquehanna International Group, LLPInstitution
0.30%24,90813Fas of Mar 31, 2026
Adar1 Capital Management, LLCInstitution
0.28%23,18013Fas of Mar 31, 2026

13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F, as of Mar 31, 2026

46 holders · 3.12M shares · 24 new positions · 33 increased · 9 reduced · 4 closed

HolderShares% outstandingChg q/qFiled
Ikarian Capital, LLC508.6K6.17%+309.0KMay 15, 2026
Squadron Capital Management LLC450.0K5.46%−80.0KMay 15, 2026
Eversept Partners, LP295.0K3.58%+295.0KnewMay 15, 2026
Rosalind Advisors, Inc.221.6K2.69%+221.6KnewMay 14, 2026
Vanguard Capital Management LLC200.7K2.43%+200.7KnewMay 15, 2026
Aigh Capital Management LLC200.0K2.43%+200.0KnewApr 30, 2026
Stempoint Capital LP160.4K1.95%+160.4KnewMay 18, 2026
Boothbay Fund Management, LLC140.5K1.70%+85.6KMay 15, 2026

Ownership statements13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Ikarian Capital, LLC6.30%508.6K13GMay 15, 2026
Squadron Master Fund LP6.20%450.0K13GMay 15, 2026

Insider tradesForm 4

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Apr 7, 2026
John W. Higuchidirector
Purchase40,000$2.03203,797
Apr 6, 2026
Mahesh V. Pateldirector, officer: Chief Executive Officer
Purchase25,000$2.03160,679
Apr 6, 2026
John W. Higuchidirector
Purchase123,000$2.05163,797
Apr 2, 2026
Mahesh V. Pateldirector, officer: Chief Executive Officer
Purchase25,000$2.02135,679

CongressHouse and Senate disclosures

Not reported.